On 10 May 2014
Dr Datsons Labs announced that a meeting of the Board of Directors of the Company will be held on 10 May 2014, to transact the following:Increase in authorize capital of the Company from Rs 50 crore to Rs 80 crore subject to the approval of the Members of the Company.
To consider the Company's fund raising program by way of issue of equity shares on preferential basis to Non Promoters up to US$ 25.00 million, as per the Applicable provisions of the companies Act 2013 and SEBI Regulations, subject to the approval of the Members of the Company.
To consider issue of Foreign Currency convertible Bonds [FCCBs], American Depository Receipts [ADR] and Global Depository Receipts [GDR] upto US$ 25.00 million as per the Applicable provisions of the companies Act 2013 and SEBI Regulations, subject to the approval of the Members of the Company.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app